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Supplementary table 1. Murine RTqPCR primers used for the research detailed in this 
paper. 
Supplementary table 3. Expression change of genes on which sunitinib has a predicted effect, in EC isolates from tumours harvested at 1300 mm3. Log2 fold change in gene expression shown. 
Supplementary table 2. Expression change of genes on which sunitinib has a known or predicted effect, in tumour bulk harvested at each time-point. Log2 fold change in gene expression shown.   
Gene ID Gene symbol 
GeneBank 
accession no. 
Predicted 
sunitinib effect 
Non-
responsive vs. 
Untreated EC 
Responsive vs. 
Untreated EC 
Non-
responsive vs. 
Responsive EC chemokine (C-X-C motif) ligand 3 CXCL3 NM_203320 Downregulated -1.97 -0.35 -1.62 FMS-like tyrosine kinase 1 FLT1 AK005502 Downregulated -0.95 0.89 -1.84 kinase insert domain protein receptor KDR NM_010612 Downregulated -0.14 1.04 -1.18 FMS-like tyrosine kinase 3 FLT3 AK045865 Downregulated -1.04 -0.01 -1.04 ret proto-oncogene RET NM_001080780 Downregulated 0.60 1.26 -0.41 baculoviral IAP repeat-containing 5 BIRC5 NM_001012273 Downregulated 1.15 0.20 0.97 BCL2-like 11 (apoptosis facilitator) BCL2L11 NM_207680 Upregulated 1.30 -0.33 1.64 
Gene ID Gene symbol 
GeneBank 
accession no. 
Effect on 
metastasis 
Responsive vs. 
Untreated 9 
days 
Responsive vs. 
Untreated 600 
mm3 
Responsive 
vs. Untreated 
1300 mm3 bone morphogenetic protein 2 BMP2 NM_007553 Increased -3.30 -0.45 -1.05 snail homolog 2 (Drosophila) SNAI2 NM_011415 Increased -2.91 0.08 0.46 ubiquitin D UBD NM_023137 Increased -2.06 0.72 0.04 thymus cell antigen 1, theta THY1 NM_009382 Increased -1.98 -0.67 0.19 collagen triple helix repeat containing 1 CTHRC1 NM_026778 Increased -1.37 -0.71 -0.70 nitric oxide synthase 3, endothelial cell NOS3 NM_008713 Increased -1.34 -0.32 -0.24 angiopoietin-like 4 ANGPTL4 NM_020581 Increased -1.32 -1.04 0.22 heparanase HPSE NM_152803 Increased -1.30 -0.18 -0.21 O-6-methylguanine-DNA methyltransferase MGMT NM_008598 Increased -1.28 -0.52 -0.08 tumor necrosis factor superfamily, 11 TNFSF11 NM_011613 Increased -1.27 0.29 0.36 zeta-chain (TCR) associated protein kinase ZAP70 NM_009539 Increased -1.27 0.19 0.89 CD274 antigen CD274 NM_021893 Increased -1.25 -0.21 0.00 Fyn proto-oncogene FYN NM_001122893 Increased -1.13 -0.35 -0.08 tumor necrosis factor TNF NM_013693 Increased -1.11 -0.30 0.96 chemokine (C-X-C motif) receptor 4 CXCR4 NM_009911 Increased -1.07 -0.73 0.00 matrix metallopeptidase 2 MMP2 NM_008610 Increased -0.29 -1.14 -0.40 chemokine (C-X-C motif) ligand 1 CXCL1 NM_008176 Increased 0.25 1.08 0.77 TOX high mobility group box 4 TOX4 NM_023434 Increased 0.31 -0.02 1.95 chemokine (C-X-C motif) ligand 3 CXCL3 NM_203320 Increased 0.40 1.41 0.07 lysyl oxidase LOX NM_010728 Increased 0.41 -1.05 -0.29 c-fos induced growth factor FIGF NM_010216 Increased 0.42 -1.21 -0.36 syndecan binding protein SDCBP AK014678 Increased 0.60 -0.06 1.11 leukotriene B4 receptor 2 LTB4R2 NM_020490 Increased 0.74 -0.69 1.29 CD151 antigen CD151 NM_009842 Increased 1.03 0.13 0.21 inositol hexaphosphate kinase 2 IP6K2 NM_029634 Increased 1.05 -0.15 0.04 chemokine (C-X-C motif) ligand 5 CXCL5 NM_009141 Increased 1.07 0.32 0.04 S100 calcium binding protein A4 S100A4 NM_011311 Increased 1.13 0.38 0.33 bone morphogenetic protein 7 BMP7 NM_007557 Increased 2.34 -0.14 0.54 
Supplementary table 4. Expression change of genes that enhance metastasis in tumour bulk harvested at each time-point. Log2 fold change in gene expression shown.  
Gene ID Gene symbol 
GeneBank 
accession no. 
Predicted 
sunitinib effect 
Responsive vs 
Untreated 9 
days 
Responsive vs 
Untreated 600 
mm3 
 Responsive vs 
Untreated 
1300 mm3 kit oncogene KIT NM_001122733 Downregulated -2.33 -0.78 0.27 platelet derived growth factor receptor, beta PDGFRB NM_001146268 Downregulated -2.11 -0.41 -0.60 CD69 antigen CD69 NM_001033122 Downregulated -2.00 0.47 0.47 Vascular endothelial growth factor receptor 2 VEGFR2 NM_010612 Downregulated -1.63 -0.18 -0.95 FMS-like tyrosine kinase 3 Flt3 NM_010229 Downregulated -1.53 -0.21 -0.82 colony stimulating factor 1 receptor Csf1r NM_001037859 Downregulated -1.35 -0.91 -0.82 interleukin 2 receptor, alpha IL2RA NM_008367 Downregulated -1.28 -0.24 0.99 
Gene ID Gene symbol 
GeneBank 
accession no. 
Effect of 
metastasis 
Non-
responsive vs. 
Untreated W 
 Responsive 
vs. Untreated 
W 
Non-responsive 
vs. Responsive 
W TOX high mobility group box family member 4 TOX4 NM_023434 Increased -1.96 1.95 -3.94 insulin-like growth factor 1 IGF1 NM_010512 Increased -1.52 0.10 -1.62 cadherin 2 CDH2 NM_007664 Increased -1.12 -0.11 -1.01 neurotrophic tyrosine kinase, receptor, type 2 NTRK2 NM_001025074 Increased -1.12 0.64 -1.74 leukotriene B4 receptor 2 LTB4R2 NM_020490 Increased -1.01 1.29 -2.04 bone morphogenetic protein 2 BMP2 NM_007553 Increased -0.02 -1.05 0.91 syndecan binding protein SDCBP AK014678 Increased 0.77 1.11 -0.51 netrin 1 NTN1 NM_008744 Increased 1.01 0.30 0.72 CD44 antigen CD44 NM_009851 Increased 1.02 0.17 0.85 Notch gene homolog 1 (Drosophila) NOTCH1 NM_008714 Increased 1.16 0.75 0.40 ubiquitin D UBD NM_023137 Increased 1.23 0.04 1.17 melanoma cell adhesion molecule MCAM NM_023061 Increased 1.27 -0.05 1.35 chemokine (C-X-C motif) ligand 5 CXCL5 NM_009141 Increased 1.55 0.04 1.52 
Supplementary table 5. Expression change of genes that enhance metastasis in tumour bulk harvested at 1300 mm3. Log2 fold change in gene expression shown.  
Gene ID Gene symbol 
GeneBank 
accession no. 
Effect on 
endothelial 
migration 
Responsive 
vs. Untreated 
9 days 
Responsive 
vs. Untreated 
600 mm3 
 Responsive 
vs. Untreated 
1300 mm3 tenascin N TNN NM_177839 Increased -3.45 -0.42 -0.14 bone morphogenetic protein 2 BMP2 NM_007553 Increased -3.30 -0.45 -1.05 matrix metallopeptidase 13 MMP13 NM_008607 Increased -2.90 1.24 -0.75 wingless-related MMTV integration site 5A WNT5A NM_009524 Increased -2.86 -0.36 0.17 endothelial cell-specific adhesion molecule ESAM NM_027102 Increased -2.62 -0.29 -1.08 integrin alpha 9 ITGA9 NM_133721 Increased -2.33 0.20 -0.47 EGF-like domain 7 EGFL7 NM_178444 Increased -2.00 -0.38 -0.42 elastin ELN NM_007925 Increased -1.65 -1.04 -0.15 growth arrest specific 6 GAS6 NM_019521 Increased -1.64 -0.75 0.12 phosphoinositide-3-kinase, catalytic, gamma PIK3CG NM_020272 Increased -1.63 -0.46 -0.34 tumor necrosis factor (ligand) superfamily, 10 TNFSF10 NM_009425 Increased -1.62 1.01 -0.03 tachykinin 1 TAC1 NM_009311 Increased -1.60 0.35 0.01 insulin-like growth factor binding protein 3 IGFBP3 NM_008343 Increased -1.59 -0.79 -0.43 Rac/Cdc42 guanine nucleotide exchange factor 6 ARHGEF6 NM_152801 Increased -1.52 -0.08 0.18 sphingosine-1-phosphate receptor 3 S1PR3 NM_010101 Increased -1.50 -1.03 0.16 sphingosine-1-phosphate receptor 1 S1PR1 NM_007901 Increased -1.44 -0.70 -0.96 endothelial-specific receptor tyrosine kinase TEK NM_013690 Increased -1.42 -0.45 -0.38 nitric oxide synthase 3, endothelial cell NOS3 NM_008713 Increased -1.34 -0.32 -0.24 heparanase HPSE NM_152803 Increased -1.30 -0.18 -0.21 chemokine (C-C motif) ligand 5 CCL5 NM_013653 Increased -1.25 -0.15 0.43 phosphodiesterase 2A, cGMP-stimulated PDE2A NM_001143848 Increased -1.21 -0.77 -0.62 protein kinase D1 PRKD1 NM_008858 Increased -1.13 -0.07 -0.51 GATA binding protein 1 GATA1 NM_008089 Increased -0.82 -1.45 -0.60 pleiotrophin PTN NM_008973 Increased -0.34 -0.15 3.23 matrix metallopeptidase 2 MMP2 NM_008610 Increased -0.29 -1.14 -0.40 chemokine (C-X-C motif) ligand 1 CXCL1 NM_008176 Increased 0.25 1.08 0.77 teratocarcinoma-derived growth factor 1 TDGF1 NM_011562 Increased 0.30 0.56 1.03 lysyl oxidase LOX NM_010728 Increased 0.41 -1.05 -0.29 c-fos induced growth factor FIGF NM_010216 Increased 0.42 -1.21 -0.36 gastrin releasing peptide GRP NM_175012 Increased 0.49 0.47 -2.22 syndecan 4 SDC4 NM_011521 Increased 0.73 -0.55 1.01 adrenomedullin ADM NM_009627 Increased 0.78 -1.31 0.10 CD151 antigen CD151 NM_009842 Increased 1.03 0.13 0.21 angiopoietin 1 ANGPT1 NM_009640 Increased 1.77 0.15 -0.19 colony stimulating factor 2 CSF2 NM_009969 Increased 1.80 0.28 0.06 kininogen 1 KNG1 NM_001102411 Increased 2.58 -0.08 -0.09 calcitonin/calcitonin-related polypeptide, alpha CALCA NM_001033954 Increased 2.73 -0.08 0.67 
Supplementary table 6. Expression change of genes that enhance endothelial migration in tumour bulk harvested at each time-point. Log2 fold change in gene expression shown.  
